Since anti-TNF-α treatment has emerged as the central target to ameliorate IBD [21], this emphasizes the potential importance of the observed PKD1-induced downregulation of TNF-α in RAW264.7 cells. The gene discussed is PKD1; the disease is inflammatory bowel disease.